Latest Industry Insights

The biotech/genetic engineering company Colossal – co-founded in 2021 by renowned geneticist Professor George Church and serial entrepreneur Ben Lamm – announced it has begun a de-extinction project of the thylacine – an Australian marsupial commonly referred to as the “Tasmanian tiger”. Technology Networks interviewed the team to learn more.

To understand how machine learning methods and new software capabilities are helping proteomics researchers gain greater depth in their analyses, Technology Networks recently interviewed Tharan Srikumar, product manager in bioinformatics at Bruker Daltonics.

Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.

To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.

We spoke to Dr. Audrey Dubourg, product manager at CN Bio to find out more about how its organ-on-chip platform could bridge the gap between the current 2D models and animal models, providing human-relevant insights into diseases such as non-alcoholic steatohepatitis.

Today’s treatments for AD are limited and unsatisfactory. This article explores a drug development effort that is taking a completely different approach – not trying to cure the disease but actually repair the damage.

To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.

Research is advancing exciting areas of science at an unprecedented pace, but the disposable materials, powered equipment and shipping associated with experiments, sample storage and transport of reagents contribute to high energy consumption and significant waste. How are researchers bringing sustainability to scientific discovery?

Technology Networks had the pleasure of talking to Wilfredo Marín to learn more about OPC UA and how it is suited to biobanking and cell and gene therapy development.

This article explores how automated tools are helping researchers to algorithmically “unmix” spectral ranges – producing faster, smarter and higher-quality data and providing new possibilities for interpreting image data.